CD19 and neoplasm: Reports in the literature suggest markers for neurotoxicity associated with BCMA-directed CAR T-cell therapies are similar to those with CD19-directed immunotherapies, and have demonstrated a correlation of ICANS with the presence and severity of CRS, and high tumor burden [7, 8, 10, 23, 24].